Ipamorelin + CJC-1295 No-DAC

Technical specifications

Reference specifications describe the material. They do not replace the analytical results for a specific batch.

Chemical name

Blend of Ipamorelin and Mod GRF (1-29), CJC-1295 without DAC

Sequence

See the individual Ipamorelin and CJC-1295 No-DAC pages

Molecular formula

Not available

Molecular weight

Not available

CAS number

Not available

Form

Lyophilized powder

Appearance

White to off-white solid

Purity specification

Declared in the batch certificate

Identity

Declared in the batch certificate

Solubility

Soluble in sterile water and bacteriostatic water

Storage

−20 °C, protected from light

Stability after reconstitution

Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Batch documentation

Review documentation for the product and variant you are purchasing. A reference specification, a research publication and an individual batch certificate are different sources. Ask support which documents are available for your chosen variant and batch. No analytical result should be assumed from a catalog specification.

Laboratory handling

Reconstitution

Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage

Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment

Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Research references

The cited studies examine the individual components, not this combined preparation. Different molecular targets do not, by themselves, establish synergy. Exposure data for ipamorelin cannot be presented as the pharmacokinetics of the blend, and studies of CJC-1295 with DAC do not establish the behavior of the variant without DAC.

1. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

   Pharm Res · 1999 · PMID 10496658

2. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

   Int J Colorectal Dis · 2014 · PMID 25331030

3. Ipamorelin, the first selective growth hormone secretagogue

   Eur J Endocrinol · 1998 · PMID 9849822

4. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

   Front Endocrinol (Lausanne) · 2026 · PMID 42395176

Frequently asked questions